IFM’s Glick Becomes Executive Chairman, Seidel Promoted to CEO

Gary Glick, co-founder and CEO of IFM Therapeutics, is moving on from his executive role to become executive chairman of the company’s board of directors. To take his place, Boston-based IFM promoted Martin Seidel, the company’s vice president of research and development, to CEO. He is also joining the company’s board. The personnel changes came as IFM announced $55.5 million in new financing and plans for a new subsidiary and an incubator, both of which are focused on developing treatments for inflammatory diseases and cancer.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.